Cargando…

mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high infectivity, pathogenicity, and variability, is a global pandemic that severely affected public health and the world economy. The development of safe and effective vaccines is crucia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Yingqi, Hou, Chen, Li, Yonghao, Zheng, Kang, Wang, Chuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813741/ https://www.ncbi.nlm.nih.gov/pubmed/35126377 http://dx.doi.org/10.3389/fimmu.2021.821538

Ejemplares similares

Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients
por: Fattizzo, Bruno, et al.
Publicado: (2022)

A novel mRNA vaccine, SYS6006, against SARS-CoV-2
por: Xu, Ke, et al.
Publicado: (2023)

Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2
por: Monzon-Posadas, Werner O., et al.
Publicado: (2023)

Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders
por: Kasai, Ryousuke, et al.
Publicado: (2023)

Design and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine
por: Qin, Jane, et al.
Publicado: (2023)

Impact of SARS-CoV-2 mRNA vaccine on arthritis condition in rheumatoid arthritis
por: Takatani, Ayuko, et al.
Publicado: (2023)

Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients
por: Oyaert, Matthijs, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients
por: Pascale, Sara Pasquina, et al.
Publicado: (2022)

Early immunological responses to the mRNA SARS-CoV-2 vaccine in patients with neuromuscular disorders
por: Iwayama, Hideyuki, et al.
Publicado: (2022)

SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern
por: Ma, Qinhai, et al.
Publicado: (2023)

Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities
por: Wang, Bolin, et al.
Publicado: (2023)

Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates
por: Wu, Yixin, et al.
Publicado: (2022)

Age-adjusted impact of prior COVID-19 on SARS-CoV-2 mRNA vaccine response
por: Nakagama, Sachie, et al.
Publicado: (2023)

SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans
por: Forgacs, David, et al.
Publicado: (2021)

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
por: Zitt, Emanuel, et al.
Publicado: (2021)

Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination
por: Al Jurdi, Ayman, et al.
Publicado: (2022)

Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination
por: Taus, Ellie, et al.
Publicado: (2023)

Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report
por: Rysava, Romana, et al.
Publicado: (2022)

Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2
por: Özbay Kurt, Feyza Gül, et al.
Publicado: (2022)

SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia
por: Merid, Yared, et al.
Publicado: (2023)

Localized Delayed T-cell Mediated Hypersensitivity After mRNA SARS-CoV-2 Vaccination
por: Jhawar, Nikita, et al.
Publicado: (2023)

A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine
por: Jawalagatti, Vijayakumar, et al.
Publicado: (2022)

Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination
por: Hernández-Luis, Pablo, et al.
Publicado: (2022)

Sex, Age, and Ethnic Background Shape Adaptive Immune Responses Induced by the SARS-CoV-2 mRNA Vaccine
por: Bai, Jie, et al.
Publicado: (2022)

Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients
por: Baron, Frédéric, et al.
Publicado: (2022)

Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses
por: Almendro-Vázquez, Patricia, et al.
Publicado: (2022)

Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine
por: Saresella, Marina, et al.
Publicado: (2022)

Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption
por: Gröning, Remigius, et al.
Publicado: (2023)

Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial
por: Usmani, Salman Sadullah, et al.
Publicado: (2020)

Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort
por: Beilhack, Georg, et al.
Publicado: (2021)

mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals
por: Longet, Stephanie, et al.
Publicado: (2022)

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines
por: Mueller-Enz, Magdalena, et al.
Publicado: (2023)

Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine
por: Ciabattini, Annalisa, et al.
Publicado: (2021)

Neutralizing Activity and SARS-CoV-2 Vaccine mRNA Persistence in Serum and Breastmilk After BNT162b2 Vaccination in Lactating Women
por: Yeo, Kee Thai, et al.
Publicado: (2022)

Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern
por: Schwarze, Mandy, et al.
Publicado: (2022)

Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy
por: Duan, Li-Juan, et al.
Publicado: (2022)

Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination
por: Salgado Del Riego, Estefanía, et al.
Publicado: (2022)

Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA
por: Stolovich-Rain, Miri, et al.
Publicado: (2023)

Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao
por: Ng, Hoi Man, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uogoseghokdpl5mk923o794a7e